FRAXA Research Foundation Features GEXVal's Development Program

GEXVal Inc.
January 6, 2025

We are delighted to announce that FRAXA Research Foundation¹⁾ has featured GEXVal Inc.'s (President and CEO: Juran Kato, PhD; Location: Fujisawa, Kanagawa, Japan; hereinafter "GEXVal") development program on their website on January 2, 2025.

The original article can be viewed here:
[GEXVal and FRAXA Collaborate to Advance Fragile X Research with Phase 2a Trial]
(URL: https://www.fraxa.org/gexval-and-fraxa-collaborate-to-advance-fragile-x-research-with-phase-2a-trial/)

For GEXVal's press release on this matter, please visit:
[GEXVal Selected for AMED²⁾ Strengthening Program for Pharmaceutical Startup Ecosystem]
(https://gexval.com/en/rd-en/gexval-selected-for-ameds-strengthening-program-for-pharmaceutical-startup-ecosystem/)

Through our innovative pharmacoinformatics technology, GEXVal is dedicated to addressing unmet medical needs and engaging in clinical development, with a focus on rare diseases, ensuring that no patient is left behind. We are committed to delivering novel and life changing therapeutic options to patients and their families as quickly as possible.

1) About FRAXA Research Foundation (FRAXA): FRAXA is a nonprofit organization headquartered in Massachusetts, USA, dedicated to supporting research and raising awareness for the development of treatments for Fragile X Syndrome ³⁾.
For more information, visit https://www.fraxa.org

2) About Japan Agency for Medical Research and Development (AMED): AMED is an agency that supports research and development necessary for medical advancement, providing comprehensive support from basic research to practical application in the development of new treatments and medicines.
For more information, visit https://www.amed.go.jp/en/aboutus/index.html

3) About Fragile X syndrome (FXS): Fragile X syndrome is a rare neurological developmental disorder classified within the autism spectrum. According to FRAXA Research Foundation, it is considered the most common inherited cause of autism and intellectual disabilities.

For more information:
- National Organization for Rare Disorders (NORD): https://rarediseases.org/rare-diseases/fragile-x-syndrome/
- Orphanet: https://www.orpha.net/en/disease/detail/908?name=fxs&mode=name 
- FRAXA Research Foundation: https://www.fraxa.org

For further information:
Head of Corporate office
Atsushi Sugizaki
info@gexval.com